Aclaris Therapeutics
ACRS
82 hedge funds and large institutions have $58.6M invested in Aclaris Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 25 closing their positions.
1,017% more call options, than puts
Call options by funds: $67K | Put options by funds: $6K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.79% less ownership
Funds ownership: 74.17% → 71.38% (-2.8%)
16% less funds holding
Funds holding: 98 → 82 (-16)
26% less capital inflows, than outflows
Capital inflows: $5.84M | Capital outflows: $7.86M
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
64% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.55M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.12M |
| 3 |
Stonepine Capital Management
Bend,
Oregon
|
+$652K |
| 4 |
Renaissance Technologies
New York
|
+$550K |
| 5 |
Morgan Stanley
New York
|
+$361K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.1M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$795K |
| 3 |
Goldman Sachs
New York
|
-$754K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$626K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$482K |
ACRS Hedge Fund Activity: Q3 2024 in Review
82 of the 6,989 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2024, worth a combined $58.6M — up 0.73% from $58.1M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ACRS and 9 opened new positions — a net loss of 16 holders — while 29 trimmed existing stakes and 21 added.
The largest buyer was BML Capital Management, adding an estimated $1.55M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $1.1M sold.
- 82 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2024, down from 98 in Q2 2024.
- Funds reported $58.6M of Aclaris Therapeutics stock for Q3 2024, up 0.73% quarter-over-quarter.
- 9 funds opened new Aclaris Therapeutics positions in Q3 2024 and 25 closed out, a net change of -16 holders.
- The largest Aclaris Therapeutics buyer in Q3 2024 was BML Capital Management, an estimated $1.55M added.
- The largest Aclaris Therapeutics seller in Q3 2024 was Bain Capital Life Sciences Investors, an estimated $1.1M sold.
Based on aggregated 13F filings for Q3 2024.